The purpose of this study is to assess the relative effectiveness, safety, and durability of the most commonly used prescription (zolpidem, trazodone) and over-the-counter (OTC) (melatonin, diphenhydramine) medications for insomnia, as well as a less commonly used prescription that may have a better risk/benefit profile (doxepin).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Relative treatment response rates during acute (1-month) treatment phase
Timeframe: From treatment initiation to 1 month after treatment initiation
Relative safety and tolerability based on side effects during acute (1-month) treatment phase
Timeframe: From treatment initiation to 1 month after treatment initiation
Relative effects on daytime symptoms and function during acute (1-month) treatment phase
Timeframe: From treatment initiation to 1 month after treatment initiation
Durability of treatment response during longer-term maintenance (1-6 months) treatment phase
Timeframe: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation
Relative safety and tolerability based on side effects during longer-term maintenance (1-6 months) phase
Timeframe: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation
Durability of effects on daytime symptoms and function during longer-term maintenance (1-6 months) phase
Timeframe: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation